Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorFinance
Current SymbolNASDAQ:CRON
Previous Symbol
CUSIPN/A
Phone212-590-9070
Debt
Debt-to-Equity RatioN/A
Current Ratio9.03
Quick Ratio6.85
Price-To-Earnings
Trailing P/E Ratio1,240.61
Forward P/E Ratio-310.15
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.15 million
Price / Sales697.81
Cash Flow$0.0183 per share
Price / Cash Flow676.81
Book Value$0.47 per share
Price / Book26.40
Profitability
EPS (Most Recent Fiscal Year)$0.01
Net Income$1.92 million
Net Margins-45.72%
Return on Equity-3.22%
Return on Assets-3.02%
Miscellaneous
Employees148
Outstanding Shares177,180,000
Market Cap$2.25 billion
OptionableOptionable
Cronos Group (NASDAQ:CRON) Frequently Asked Questions
What is Cronos Group's stock symbol?
Cronos Group trades on the NASDAQ under the ticker symbol "CRON."
How were Cronos Group's earnings last quarter?
Cronos Group Inc (NASDAQ:CRON) issued its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.03) EPS for the quarter, missing the Zacks' consensus estimate of ($0.02) by $0.01. The company had revenue of $3.76 million for the quarter, compared to the consensus estimate of $3.56 million. Cronos Group had a negative return on equity of 3.22% and a negative net margin of 45.72%. The business's quarterly revenue was up 187.0% on a year-over-year basis. View Cronos Group's Earnings History.
When is Cronos Group's next earnings date?
What price target have analysts set for CRON?
3 Wall Street analysts have issued 12-month price objectives for Cronos Group's shares. Their forecasts range from $9.00 to $9.00. On average, they expect Cronos Group's stock price to reach $9.00 in the next year. This suggests that the stock has a possible downside of 26.7%. View Analyst Price Targets for Cronos Group.
What is the consensus analysts' recommendation for Cronos Group?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cronos Group.
Has Cronos Group been receiving favorable news coverage?
News headlines about CRON stock have been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cronos Group earned a coverage optimism score of 2.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days.
Are investors shorting Cronos Group?
Cronos Group saw a decrease in short interest in November. As of November 30th, there was short interest totalling 25,422,941 shares, a decrease of 11.4% from the November 15th total of 28,682,369 shares. Based on an average daily volume of 4,590,408 shares, the short-interest ratio is currently 5.5 days. View Cronos Group's Current Options Chain.
Who are some of Cronos Group's key competitors?
Some companies that are related to Cronos Group include Canopy Growth (CGC), Aurora Cannabis Inc (TSE) (ACB), STADA Arzneimit/AKT o.N. (STDAF), USANA Health Sciences (USNA), Foamix Pharmaceuticals (FOMX), Chromadex (CDXC), Mediwound (MDWD), Natural Alternatives International (NAII), China Jo-Jo Drugstores (CJJD), Pharmacyte Biotech (PMCB), Mannatech (MTEX), GLG Life Tech (GLGLF), Cyanotech (CYAN), FitLife Brands (FTLF) and Tauriga Sciences (TAUG).
Who are Cronos Group's key executives?
Cronos Group's management team includes the folowing people:
- Mr. Michael Gorenstein, Chairman, Pres & CEO (Age 31)
- Mr. William Hilson, Chief Financial Officer
- Mr. David Hsu, Chief Operating Officer
- Ms. Xiuming Shum, Gen. Counsel & Corp. Sec.
- Mr. Jeffrey Jacobson, VP of Bus. Devel.
Who are Cronos Group's major shareholders?
Cronos Group's stock is owned by a number of of institutional and retail investors. Top institutional investors include Morgan Stanley (0.47%), Gerber Kawasaki Wealth & Investment Management (0.12%), Essex Investment Management Co. LLC (0.08%), Wedbush Securities Inc. (0.07%), Commonwealth Equity Services LLC (0.05%) and Quantbot Technologies LP (0.04%).
Which institutional investors are selling Cronos Group stock?
CRON stock was sold by a variety of institutional investors in the last quarter, including Lourd Capital LLC and Tower Research Capital LLC TRC .
Which institutional investors are buying Cronos Group stock?
CRON stock was purchased by a variety of institutional investors in the last quarter, including Gerber Kawasaki Wealth & Investment Management, Essex Investment Management Co. LLC, Wedbush Securities Inc., Morgan Stanley, MML Investors Services LLC, Quantbot Technologies LP, USA Mutuals Advisors Inc. and First Republic Investment Management Inc..
How do I buy shares of Cronos Group?
Shares of CRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cronos Group's stock price today?
One share of CRON stock can currently be purchased for approximately $12.28.
How big of a company is Cronos Group?
Cronos Group has a market capitalization of $2.25 billion and generates $3.15 million in revenue each year. The company earns $1.92 million in net income (profit) each year or $0.01 on an earnings per share basis. Cronos Group employs 148 workers across the globe.
What is Cronos Group's official website?
How can I contact Cronos Group?
Cronos Group's mailing address is 720 KING STREET W SUITE 320, TORONTO A6, M5V 2T3. The company can be reached via phone at 212-590-9070.
MarketBeat Community Rating for Cronos Group (NASDAQ CRON)
MarketBeat's community ratings are surveys of what our community members think about Cronos Group and other stocks. Vote "Outperform" if you believe CRON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRON will underperform the S&P 500 over the long term. You may vote once every thirty days.
